Earnings Call Summary | Steris PLC(STE.US) Q4 2024 Earnings Conference
Earnings Call Summary | Steris PLC(STE.US) Q4 2024 Earnings Conference
The following is a summary of the STERIS Plc (STE) Q4 2024 Earnings Call Transcript:
以下是STERIS Plc（STE）2024年第四季度财报电话会议记录的摘要：
Financial Performance:
财务业绩：
STERIS Plc reported total Q4 revenue growth of 10%, with adjusted earnings per diluted share at $2.58.
Full year revenue growth reached 12%, with adjusted earnings per share at $8.83.
Gross margin for the quarter declined to 42.6% while EBIT margin decreased to 23.7%.
Capital expenditures totaled $360 million while the total debt sat at $3.2 billion, with a debt-to-EBITDA ratio of 2.1.
Free cash flow was $620 million for the fiscal year 2024.
STERIS Plc报告称，第四季度总收入增长了10％，调整后的摊薄后每股收益为2.58美元。
全年收入增长达到12％，调整后的每股收益为8.83美元。
该季度的毛利率下降至42.6％，而息税前利润率降至23.7％。
资本支出总额为3.6亿美元，总债务为32亿美元，债务与息税折旧摊销前利润的比率为2.1。
2024财年的自由现金流为6.2亿美元。
Business Progress:
业务进展：
The Healthcare segment achieved 13% constant currency organic revenue growth, showing continuous progress.
They expect growth in AST, Healthcare, and Life Sciences segments in the upcoming fiscal year.
STERIS provided FY 2025 projections, expecting a 6.5% to 7.5% increase in as-reported revenue.
A targeted restructuring plan is announced, which includes the restructuring of the Healthcare Surgical Capital business in Europe and other actions.
The company decided to divest two businesses during the year, including the Dental segment.
医疗保健板块实现了13％的固定货币有机收入增长，显示出持续的进步。
他们预计，在下一个财年，AST、医疗保健和生命科学板块将实现增长。
STERIS提供了2025财年的预测，预计报告的收入将增长6.5％至7.5％。
宣布了一项有针对性的重组计划，其中包括重组欧洲医疗外科资本业务和其他行动。
该公司决定在年内剥离两项业务，包括牙科板块。
More details: Steris PLC IR
更多详情： Steris PLC 红外线
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。